# US 2019/0167527 A1 · Topical antimicrobial compositions and methods of formulating the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0167527 A1
- Document ID: US20190167527A1
- Status: Published application
- Kind: A1
- Application number: 16/270,335
- Filed: 2019-02-07
- Published: 2019-06-06
- Earliest claimed: 2015-08-05
- Assignees: CMPD Licensing, LLC
- Applicants: CMPD Licensing, LLC
- Inventors: Jay Richard Ray, II
- Web page: https://patentgrep.com/patent/US20190167527A1

## CPC

- A61J 7/0007: {Pill breaking or crushing devices}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/17: having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine (isoureas, isothioureas A61K31/155; sulfonylureas A61K31/64)
- A61K 31/196: the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A61K 31/351: not condensed with another ring
- A61K 31/4196: 1,2,4-Triazoles
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/5355: Non-condensed oxazines and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/5383: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/546: containing further heterocyclic rings, e.g. cephalothin
- A61K 31/7036: having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61J: CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of formulating a topical composition may include combining a powder including an antimicrobial pharmaceutical drug and a topical carrier. The powder may include at least a portion of a crushed oral tablet. The crushed oral tablet may include at least a portion of the antimicrobial pharmaceutical drug. The antimicrobial pharmaceutical drug may be selected from voriconazole, fluconazole, linezolid, levofloxacin, ciprofloxacin, or combination thereof.

## Claims

### Claim 1

A method of formulating a topical composition, the method comprising:
combining:
a powder comprising an antimicrobial pharmaceutical drug; and
a topical carrier,
wherein the powder comprises at least a portion of a crushed oral tablet comprising the antimicrobial pharmaceutical drug, and wherein the antimicrobial pharmaceutical drug is selected from voriconazole, fluconazole, linezolid, levofloxacin, ciprofloxacin, or combination thereof.

### Claim 2 (depends on 1)

The method of claim 1, further comprising crushing the oral tablet comprising the antimicrobial pharmaceutical drug.

### Claim 3 (depends on 2)

The method of claim 2, wherein the oral tablet comprises a voriconazole 50 mg, 100 mg, or 200 mg oral tablet.

### Claim 4 (depends on 2)

The method of claim 2, wherein the oral tablet comprises a fluconazole 100 mg or 200 mg oral tablet.

### Claim 5 (depends on 2)

The method of claim 2, wherein the oral tablet comprises a linezolid 600 mg oral tablet.

### Claim 6 (depends on 2)

The method of claim 2, wherein the oral tablet comprises a ciprofloxacin 250 mg, 500 mg, or 750 mg oral tablet.

### Claim 7 (depends on 2)

The method of claim 2, wherein the oral tablet comprises a levofloxacin 250 mg, 500 mg, or 750 mg oral tablet.

### Claim 8 (depends on 1)

The method of claim 1, wherein the topical carrier comprises a solution, cream, ointment, gel, or foam.

### Claim 9 (depends on 8)

The method of claim 8, wherein the topical carrier comprises a commercially available medicated composition comprising at least one additional active pharmaceutical drug.

### Claim 10 (depends on 2)

The method of claim 2, further comprising removing a film coating on the oral tablet prior to crushing the oral tablet comprising agitating the oral tablet for approximately 5 to approximately 20 seconds while the oral tablet is contacted with a solvent, and, thereafter, removing the solvent from contact with the oral tablet.

### Claim 11

A method of treating a bacteria or fungal infection, the method comprising:
topically administering a composition comprising at least a portion of an oral tablet combined with a carrier to an affected external skin or nail region or an anal or vaginal orifice,
wherein the oral tablet comprises an antimicrobial pharmaceutical drug selected from voriconazole, fluconazole, linezolid, levofloxacin, ciprofloxacin, or combination thereof.

### Claim 12 (depends on 11)

The method of claim 11, wherein the composition comprises a solution, and wherein topically administering the composition comprises administering to skin or a nail of a foot or hand in a footbath.

### Claim 13 (depends on 11)

The method of claim 11, wherein the composition comprises an irrigation solution, and wherein topically administering the composition comprises irrigating the affected external skin or nail region or anal or vaginal orifice.

### Claim 14 (depends on 11)

The method of claim 11, wherein the composition comprises a nail lacquer solution, wherein and topically administering the composition comprises applying the nail lacquer solution to a nail of a foot or hand.

### Claim 15 (depends on 11)

The method of claim 11, further comprising formulating the composition, wherein formulating the composition comprises combining:
a powder comprising at least a portion of the oral tablet having been crushed to generate the powder; and
the carrier.

### Claim 16 (depends on 15)

The method of claim 15, wherein the oral tablet comprises a voriconazole 50 mg oral tablet, voriconazole 100 mg oral tablet, voriconazole 200 mg oral tablet, fluconazole 100 mg oral tablet, fluconazole 200 mg oral tablet, or combination thereof.

### Claim 17 (depends on 15)

The method of claim 15, wherein the oral tablet comprises a linezolid 600 mg oral tablet, ciprofloxacin 250 mg oral tablet, ciprofloxacin 500 mg oral tablet, ciprofloxacin 750 mg oral tablet, levofloxacin 250 mg oral tablet, levofloxacin 500 mg oral tablet, levofloxacin 750 mg oral tablet, or combination thereof.

### Claim 18 (depends on 15)

The method of claim 15, wherein the carrier comprises a cream, ointment, gel, foam, or powder.

### Claim 19 (depends on 18)

The method of claim 18, wherein the carrier comprises a commercially available medicated composition comprising at least one additional active pharmaceutical drug.

### Claim 20 (depends on 15)

The method of claim 15, further comprising:
crushing the oral tablet; and
removing a film coating on the oral tablet prior to crushing the oral tablet, wherein removing the film coating comprises agitating the oral tablet for approximately 5 to approximately 20 seconds while the oral tablet is contacted with a solvent, and, thereafter, removing the solvent from contact with the oral tablet.
